Results 111 to 120 of about 175,700 (308)

Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem   +5 more
wiley   +1 more source

The gut–eye axis: from brain neurodegenerative diseases to age-related macular degeneration

open access: yesNeural Regeneration Research
Age-related macular degeneration is a serious neurodegenerative disease of the retina that significantly impacts vision. Unfortunately, the specific pathogenesis remains unclear, and effective early treatment options are consequently lacking.
Qianzi Jin   +4 more
doaj   +1 more source

New and emerging technologies for the treatment of inherited retinal diseases: a horizon scanning review. [PDF]

open access: yes, 2015
The horizon scanning review aimed to identify new and emerging technologies in development that have the potential to slow or stop disease progression and/or reverse sight loss in people with inherited retinal diseases (IRDs).
Michaelides, M   +4 more
core  

Rao, Anil; Chandra, Shruti; Sivaprasad, Sobha; (2022) Prediction of treatment response in patients with neovascular age-related macular degeneration [PDF]

open access: gold, 2022
Anil Rao   +99 more
openalex   +1 more source

Fluid/function correlation using AI‐based quantification versus central subfield thickness in treatment‐naïve and pre‐treated patients with neovascular AMD in a real‐world setting

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between best‐corrected visual acuity (BCVA) and quantitative macular fluid volumes, compared to central subfield thickness (CST) in treatment‐naïve and previously treated patients with active neovascular age‐related macular degeneration (nAMD).
Anna Eidenberger   +15 more
wiley   +1 more source

Age-related macular degeneration

open access: yesClinical Ophthalmology, 2011
Giuseppe Querques¹, Fernando Onofrio Avellis1,2, Lea Querques1,3, Francesco Bandello³, Eric H Souied¹ ¹Service d'Ophtalmologie, Centre Hospitalier Intercommunal Créteil, Université Paris ...
Querques G   +4 more
doaj  

Global Insights from Patients, Providers, and Staff on Challenges and Solutions in Managing Neovascular Age-Related Macular Degeneration

open access: yesOphthalmology and Therapy
Introduction Neovascular age-related macular degeneration is a global public-health concern, associated with a considerable burden to individuals, healthcare systems, and society.
Anat Loewenstein   +22 more
doaj   +1 more source

Iloprost for Age‐Related Macular Degeneration: Long‐Term Efficacy Evaluation [PDF]

open access: bronze, 2002
Eleonora Gaetani   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy